{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:08:45Z","timestamp":1769645325619,"version":"3.49.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although vaccines targeting tissue differentiation Ags represent a promising strategy for cancer immunotherapy, the risk of triggering autoimmune damage to normal tissues remains to be determined. Immunizing against a melanoma-associated Ag, dopachrome tautomerase (DCT), which normal melanocytes and glial cells also express, allowed concurrent analysis of autoimmune consequences in multiple tissues. We show that vaccination with recombinant adenovirus expressing DCT elicited a strong CTL response in C57BL\/6 mice, leading to protection against intracranial challenge with B16-F10 melanoma cells. Both histological analysis and behavioral testing indicated that there was no evidence of neuropathology in vaccinated animals and long-term survivors. Although vitiligo or demyelination could be induced by additional stimuli (i.e., surgery or inflammation) in DCT-vaccinated mice, it did not extend beyond the inflammatory area, suggesting that there is self-regulatory negative feedback in normal tissues. These results demonstrate that it is possible to vaccinate against a tumor embedded in a vital organ that shares the target Ag.<\/jats:p>","DOI":"10.4049\/jimmunol.0901447","type":"journal-article","created":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T22:33:41Z","timestamp":1268865221000},"page":"4269-4275","source":"Crossref","is-referenced-by-count":14,"title":["Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen"],"prefix":"10.1093","volume":"184","author":[{"given":"Byram W","family":"Bridle","sequence":"first","affiliation":[{"name":"Department of Pathology and Molecular Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shucui","family":"Jiang","sequence":"additional","affiliation":[{"name":"Neurosurgery Division, Department of Surgery, McMaster University , Hamilton, Ontario,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruby","family":"Chang","sequence":"additional","affiliation":[{"name":"Neurosurgery Division, Department of Surgery, McMaster University , Hamilton, Ontario,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D","family":"Lichty","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L","family":"Bramson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghong","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,4,15]]},"reference":[{"key":"2026012808075471800_r1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1600-065X.2008.00603.x","article-title":"Immunotherapy of malignant brain tumors.","volume":"222","author":"Mitchell","year":"2008","journal-title":"Immunol. Rev."},{"key":"2026012808075471800_r2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.1100369","article-title":"Cancer immunotherapy: a treatment for the masses.","volume":"305","author":"Blattman","year":"2004","journal-title":"Science"},{"key":"2026012808075471800_r3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.smim.2008.07.001","article-title":"Specificity in cancer immunotherapy.","volume":"20","author":"Schietinger","year":"2008","journal-title":"Semin. Immunol."},{"key":"2026012808075471800_r4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2741\/1801","article-title":"Tumor antigen targets and tumor immunotherapy.","volume":"11","author":"Mufson","year":"2006","journal-title":"Front. Biosci."},{"key":"2026012808075471800_r5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/08830180701402496","article-title":"Tumor-associated antigens and biomarkers in cancer and immune therapy.","volume":"26","author":"Malyankar","year":"2007","journal-title":"Int. Rev. Immunol."},{"key":"2026012808075471800_r6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1034\/j.1600-065X.2002.18812.x","article-title":"Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.","volume":"188","author":"Engelhard","year":"2002","journal-title":"Immunol. Rev."},{"key":"2026012808075471800_r7","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1073\/pnas.96.6.2982","article-title":"Vaccination with a recombinant vaccinia virus encoding a \u201cself\u201d antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ T lymphocytes.","volume":"96","author":"Overwijk","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026012808075471800_r8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20030590","article-title":"Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.","volume":"198","author":"Overwijk","year":"2003","journal-title":"J. Exp. Med."},{"key":"2026012808075471800_r9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.0022-202X.2004.23538.x","article-title":"Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo.","volume":"124","author":"Steitz","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"2026012808075471800_r10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.cji.0000171314.00924.2b","article-title":"Autoimmune toxicities associated with the administration of anti-tumor vaccines and low-dose interleukin-2.","volume":"28","author":"Chianese-Bullock","year":"2005","journal-title":"J. Immunother."},{"key":"2026012808075471800_r11","doi-asserted-by":"crossref","first-page":"8978","DOI":"10.1200\/JCO.2005.01.6816","article-title":"Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF\u2013transduced tumor cells in metastatic melanoma patients.","volume":"23","author":"Luiten","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"2026012808075471800_r12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1196\/annals.1423.043","article-title":"Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?","volume":"1110","author":"Ram","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2026012808075471800_r13","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.","volume":"23","author":"Attia","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"2026012808075471800_r14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1034\/j.1600-065X.2002.18811.x","article-title":"Multiple pathways to tumor immunity and concomitant autoimmunity.","volume":"188","author":"Turk","year":"2002","journal-title":"Immunol. Rev."},{"key":"2026012808075471800_r15","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1158\/0008-5472.CAN-03-3227","article-title":"Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin.","volume":"64","author":"Lane","year":"2004","journal-title":"Cancer Res."},{"key":"2026012808075471800_r16","first-page":"253","article-title":"Genetic vaccination with \u201cself\u201d tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.","volume":"60","author":"Bronte","year":"2000","journal-title":"Cancer Res."},{"key":"2026012808075471800_r17","first-page":"1837","article-title":"Vaccine therapy of established tumors in the absence of autoimmunity.","volume":"9","author":"Hodge","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"2026012808075471800_r18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nm1176","article-title":"Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease.","volume":"11","author":"Lang","year":"2005","journal-title":"Nat. Med."},{"key":"2026012808075471800_r19","first-page":"2143","article-title":"Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.","volume":"150","author":"Chi","year":"1997","journal-title":"Am. J. Pathol."},{"key":"2026012808075471800_r20","first-page":"8487","article-title":"Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.","volume":"63","author":"Prins","year":"2003","journal-title":"Cancer Res."},{"key":"2026012808075471800_r21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ydbio.2006.06.006","article-title":"Dopachrome tautomerase (Dct) regulates neural progenitor cell proliferation.","volume":"296","author":"Jiao","year":"2006","journal-title":"Dev. Biol."},{"key":"2026012808075471800_r22","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/1097-0142(19840601)53:11<2550::AID-CNCR2820531129>3.0.CO;2-B","article-title":"Malignant melanoma brain metastases: review of Roswell Park Memorial Institute experience.","volume":"53","author":"Madajewicz","year":"1984","journal-title":"Cancer"},{"key":"2026012808075471800_r23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00002371-200307000-00002","article-title":"Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma.","volume":"26","author":"Liu","year":"2003","journal-title":"J. Immunother."},{"key":"2026012808075471800_r24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4049\/jimmunol.176.1.200","article-title":"The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity.","volume":"176","author":"Yang","year":"2006","journal-title":"J. Immunol."},{"key":"2026012808075471800_r25","first-page":"4895","article-title":"Identification of a shared HLA-A*0201\u2013restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2).","volume":"58","author":"Parkhurst","year":"1998","journal-title":"Cancer Res."},{"key":"2026012808075471800_r26","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1158\/0008-5472.CAN-06-4336","article-title":"Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope.","volume":"67","author":"Kianizad","year":"2007","journal-title":"Cancer Res."},{"key":"2026012808075471800_r27","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.2144\/000112517","article-title":"ImageJ for microscopy.","volume":"43","author":"Collins","year":"2007","journal-title":"Biotechniques"},{"key":"2026012808075471800_r28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1078\/0940-2993-00301","article-title":"Behavioral phenotyping of mice in pharmacological and toxicological research.","volume":"55","author":"Karl","year":"2003","journal-title":"Exp. Toxicol. Pathol."},{"key":"2026012808075471800_r29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/hbeh.1997.1382","article-title":"A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice.","volume":"31","author":"Crawley","year":"1997","journal-title":"Horm. Behav."},{"key":"2026012808075471800_r30","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hipo.1092","article-title":"Neurogranin null mutant mice display performance deficits on spatial learning tasks with anxiety related components.","volume":"11","author":"Miyakawa","year":"2001","journal-title":"Hippocampus"},{"key":"2026012808075471800_r31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1037\/0033-2909.83.3.482","article-title":"The Open-Field Test: a critical review.","volume":"83","author":"Walsh","year":"1976","journal-title":"Psychol. Bull."},{"key":"2026012808075471800_r32","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.4049\/jimmunol.172.9.5200","article-title":"CTL-dependent and -independent anti-tumor immunity is determined by the tumor not the vaccine.","volume":"172","author":"Leitch","year":"2004","journal-title":"J. Immunol."},{"key":"2026012808075471800_r33","doi-asserted-by":"crossref","first-page":"857","DOI":"10.4049\/jimmunol.172.2.857","article-title":"Dendritic cell immunization route determines CD8+ T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets.","volume":"172","author":"Dudda","year":"2004","journal-title":"J. Immunol."},{"key":"2026012808075471800_r34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1056\/NEJMe058307","article-title":"Autoimmunity and immunotherapy for cancer.","volume":"354","author":"Koon","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2026012808075471800_r35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/ni0901-789","article-title":"The risk of autoimmunity associated with tumor immunotherapy.","volume":"2","author":"Gilboa","year":"2001","journal-title":"Nat. Immunol."},{"key":"2026012808075471800_r36","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/nri2438","article-title":"Immunotherapy of autoimmunity and cancer: the penalty for success.","volume":"8","author":"Caspi","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"2026012808075471800_r37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00262-005-0042-5","article-title":"Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2.","volume":"55","author":"Steitz","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"2026012808075471800_r38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0065-2776(06)90006-6","article-title":"Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.","volume":"90","author":"Uchi","year":"2006","journal-title":"Adv. Immunol."},{"key":"2026012808075471800_r39","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2006.05.6952","article-title":"Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy.","volume":"24","author":"Kaufman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"2026012808075471800_r40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic sig-nificance of autoimmunity during treatment of melanoma with interferon.","volume":"354","author":"Gogas","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2026012808075471800_r41","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes.","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"2026012808075471800_r42","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.cgt.7700620","article-title":"A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma.","volume":"10","author":"O","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"2026012808075471800_r43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-065X.2006.00433.x","article-title":"Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors.","volume":"213","author":"Mrass","year":"2006","journal-title":"Immunol. Rev."},{"key":"2026012808075471800_r44","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.4049\/jimmunol.165.6.3128","article-title":"The brain parenchyma is permissive for full anti-tumor CTL effector function, even in the absence of CD4 T cells.","volume":"165","author":"Walker","year":"2000","journal-title":"J. Immunol."},{"key":"2026012808075471800_r45","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.it.2005.07.004","article-title":"The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms.","volume":"26","author":"Engelhardt","year":"2005","journal-title":"Trends Immunol."},{"key":"2026012808075471800_r46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1024921506081","article-title":"MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor.","volume":"64","author":"Broder","year":"2003","journal-title":"J. Neurooncol."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/184\/8\/4269\/62717268\/ji_0901447.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/184\/8\/4269\/62717268\/ji_0901447.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:08:13Z","timestamp":1769605693000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/184\/8\/4269\/8013297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2010,4,15]]},"published-print":{"date-parts":[[2010,4,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.0901447","relation":{},"ISSN":["1550-6606","0022-1767"],"issn-type":[{"value":"1550-6606","type":"electronic"},{"value":"0022-1767","type":"print"}],"subject":[],"published-other":{"date-parts":[[2010,4]]},"published":{"date-parts":[[2010,4]]}}}